Table 3.
Treatment, outcome, and complications in study population.
| Parameter | Frequency N = 100 (%) |
α-Thal (%) N = 54 (%) |
β-Thal (%) N = 46 (%) |
|---|---|---|---|
| Treatment | |||
| Antiplatelet | 26% | 3 (5.6) | 23 (50) |
| Iron chelation | 55% | 21 (38.9) | 34 (73.9) |
| Splenectomy | 33% | 8 (14.8) | 25 (54.3) |
| Complications | |||
| Abnormal plasma glucose | 16% | 9 (16.6) | 7 (15.2) |
| Abnormal liver function | 29% | 15 (27.7) | 14 (30.4) |
| Cardiomyopathy | 11% | 3 (5.5) | 8 (17.4) |
| Cholelithiasis | 35% | 15 (27.7) | 20 (43.5) |
| Cholecystectomy | 25% | 10 (18.5) | 15 (32.6) |
| EMH | 25% | 3 (5.6) | 22 (47.8) |
| Hypothyroidism | 13% | 6 (11.1) | 7 (15.2) |
| Hypogonadism | 7% | 2 (3.7) | 5 (10.9) |
| Leg ulcers | 2% | 1 (1.8) | 1 (2.2) |
| Osteoporosis | 17% | 11 (20.4) | 6 (13.0) |
| PHT | 14% | 3 (5.6) | 11 (23.9) |
| PXE | None | None | None |
| Thrombosis | 4% | 2 (3.7) | 2 (4.3) |
| Overall complications | 83% | 43 (79.6) | 40 (87) |
EMH: extramedullary hematopoiesis, PHT: pulmonary hypertension, PXE: pseudoxanthoma elasticum, α-Thal: alpha-thalassemia, and β-Thal: beta-thalassemia.